Document:

Amendment No.2 to Employment Agreement with J. David Boyle II

 Exhibit 10.12 
 AMENDMENT NO. 2 
 TO 

EMPLOYMENT AGREEMENT 
  

 
 This
Amendment No. 2 to Employment Agreement (the “Amendment”) is entered into effective the day of
3rd day of November, 2009 (the “Effective
Date”) by and between AVI BioPharma, Inc., an Oregon corporation (“Company”) and J. David Boyle II (“Employee”). 
 RECITALS 
 A. Whereas, Company and Employee are parties
to that certain Employment Agreement dated the 24th day of
July, 2008, as amended by Amendment No. 1 to Employment Agreement entered into effective the 1st day of August, 2008, copies of which are attached hereto as Exhibit A (the “Employment Agreement”). 
 B. Whereas, the Company and the Employee desire to add a provision to the Employment Agreement related to Section 280G of the Internal Revenue Code of 1986, as amended. 

Now, therefore, in consideration of the representations, warranties and covenants contained herein, the Company and the Employee agree as
follows: 
 AGREEMENT 
  

	1.	Section 23(b)(iv) is hereby added to the Employment Agreement, and shall state in its entirety as follows: 

 

	 	“(iv)	As a result of the uncertainty in the application of Section 280G and 4999 of the Code, it is possible that, despite the limitations on parachute payments provided
in this Section 23, amounts may be paid or distributed by the Company to or for the benefit of the Employee under this Agreement or otherwise which are treated as excess parachute payments. In the event that any payments received by the
Employee are determined by the IRS to be subject to the federal excise tax under Section 4999 of the Code (the “Excise Tax”), the Company shall pay the Employee as promptly as possible following such determination (but in no
event later than the end of the Employee’s taxable year in which the Employee remits the related taxes) an additional amount which may be necessary to reimburse the Employee on an after-tax basis for any Excise Tax that may be imposed on such
excess parachute payments and for any interest and penalties related to such Excise Tax that may be imposed by the IRS or a court. In addition, the Company shall indemnify and hold the Employee harmless, on an after-tax basis, from and against any
and all losses, costs, damages or expenses (including reasonable attorneys’ and accountants fees) arising out of the imposition on Employee of any Excise Tax.” 

	2.	In all other respects, the Employment Agreement shall remain unchanged and in full force and effect. 

IN WITNESS WHEREOF, the parties have executed this Amendment effective the date first set forth above. 

 

									
	AVI BioPharma, Inc.	 		 	
					
	By:	 	/s/ Leslie Hudson	 		 		 	/s/ J. David Boyle II
	Name:	 	Leslie Hudson, Ph.D.	 		 		 	J. David Boyle II
	Title:	 	Chief Executive Officer	 		 		 	

  
 -2-

 EXHIBIT A 
 Employment Agreement and Amendment No. 1 to Employment Agreement 

Previously FiledAmendment No.1 to Employment Agreement with Stephen Bevan Shrewsberry, M.D.

 Exhibit 10.14 
 AMENDMENT NO. 1 
 TO 

EMPLOYMENT AGREEMENT 
  

 
 This Amendment No. 1 to Employment Agreement (the “Amendment”) is entered into effective the 16th day of October, 2009 (the “Effective Date”) by and between AVI BioPharma, Inc., an Oregon corporation
(“Company”) and Stephen Bevan Shrewsbury, MD (“Employee”). 
 RECITALS 

A. Whereas, Company and Employee are parties to that certain Employment Agreement dated the 26th day of January, 2009, a copy of which is attached hereto as
Exhibit A (the “Employment Agreement”). 
 B. Whereas, the Company and the Employee desire to
add a provision to the Employment Agreement related to Section 280G of the Internal Revenue Code of 1986, as amended.

Now, therefore, in consideration of the representations, warranties and covenants contained herein, the Company and the Employee
agree as follows: 
 AGREEMENT 
  

	1.	Section 23(d)(iv) is hereby added to the Employment Agreement, and shall state in its entirety as follows: 

 

	 	“(iv)	As a result of the uncertainty in the application of Section 280G and 4999 of the Code, it is possible that, despite the limitations on parachute payments provided
in this Section 23, amounts may be paid or distributed by the Company to or for the benefit of the Employee under this Agreement or otherwise which are treated as excess parachute payments. In the event that any payments received by the
Employee are determined by the IRS to be subject to the federal excise tax under Section 4999 of the Code (the “Excise Tax”), the Company shall pay the Employee as promptly as possible following such
determination (but in no event later than the end of the Employee’s taxable year in which the Employee remits the related taxes) an additional amount which may he necessary to reimburse the Employee on an after-tax basis for any
Excise Tax that may be imposed on such excess parachute payments and for any interest and penalties related to such Excise Tax that may be imposed by the IRS or a court. In addition, the Company shall indemnify and hold the Employee harmless,
on an after-tax basis, from and against any and all losses, costs, damages or expenses (including reasonable attorneys’ and accountants fees) arising out of the imposition on Employee of any Excise Tax.” 

	2.	In all other respects, the Employment Agreement shall remain unchanged and in full force and effect. 

IN WITNESS WHEREOF, the parties have executed this Amendment effective the date first set forth above. 

 

									
	AVI BioPharma, Inc.	 		 	
					
	By:	 	/s/ Leslie Hudson	 		 		 	/s/ Stephen Bevan Shrewsbury
	Name:	 	Leslie Hudson, Ph.D.	 		 		 	Stephen Bevan Shrewsbury, MD
	Title:	 	Chief Executive Officer	 		 		 	

  
 - 2 -Employment Agreement between AVI Biopharma and Paul Medeiros

 Exhibit 10.15 
 EMPLOYMENT AGREEMENT 
 THIS EMPLOYMENT AGREEMENT
(“Agreement”) is made on this 15th day of May,
2009, by and between AVI BioPharma, Inc., an Oregon corporation, with its principal office at 4575 SW Research Way, Suite 200, Corvallis, Oregon, (“Company”), and Paul Medeiros, 700 Mixsell Street, Easton, Pennsylvania 18042
(“Employee”). 
 RECITALS: 
 The Company desires to hire the Employee as Senior Vice President Business Development and Chief Business Officer and the Employee desires to accept such position under the terms and conditions stated
herein. 
 NOW, THEREFORE, in consideration of the mutual benefits contained herein, the sufficiency of which the parties
acknowledge, the parties hereby agree as follows: 
 AGREEMENT: 

 

	1.	Employment Term. 

 The
term of employment (“Term”) shall commence on the Effective Date and shall continue until the first anniversary of the Effective Date, unless extended as provided below or terminated in accordance with Section 12 below.
This Agreement establishes an “at will” employment relationship, as such term is defined and used under Oregon law, between the Company and the Employee. Employee shall commence employment not later than May 19, 2009 (the
“Effective Date”). Failure to do so shall be grounds for immediate termination for Cause, as such term is defined in Section 12 hereof. Notwithstanding anything to the contrary herein, unless sooner terminated in
accordance with the terms hereof, this Agreement shall annually automatically renew for additional one-year terms unless one party notifies the other party in accordance with Section 13 hereof of its intention not to renew, such notice
to be delivered not less than 90 days before the term ends. For purposes of this Agreement, the non-renewal of the Agreement by the Company shall constitute a termination of Employee’s employment by the Company other than for Cause. 

 

	2.	Duties. 

 Employee shall
be employed as Senior Vice President Business development and Chief Business Officer and shall have such duties as are customarily associated with that position, including overall responsibility for development and execution of strategies and
tactics for transactions, alliances, mergers and acquisitions that are agreed with the Corporate Executive Team and CEO, and such other duties as may be assigned to him from time to time by the Company’s Chief Executive Officer
(“CEO”). Employee shall be a direct report of the CEO. Employee shall devote substantially all of his business time to the service of the Company throughout the Term. Employee and Company acknowledge and agree that (i) Employee
may hold certain offices within certain entities as agreed by the 

 
CEO and set forth on Exhibit A to this Agreement, (ii) Employee’s devotion of reasonable amounts of time in such capacities, so long as it does not interfere with his
performance of services hereunder, shall not conflict with the terms of this Agreement, and (iii) Exhibit A may be amended from time to time by agreement of the parties rendered in writing. 

 

	3.	Compensation. 

 (a)
Base Compensation. During the Term the Company shall compensate the Employee at an initial annual salary of Three Hundred Fifteen Thousand Dollars ($315,000.00), payable in accordance with the Company’s payroll practices in effect from
time to time, and less amounts required to be withheld under applicable law and requested to be withheld by the Employee (as increased from time to time, “Base Compensation”). The Employee’s Base Compensation shall be subject to
review for potential increase (but not decrease) on an annual basis. Except as otherwise provided in this Agreement, the Base Compensation shall be prorated for any period of service less than a full month. 

(b) Bonus. For each fiscal year of the Company that ends during the Term, the Employee shall be eligible for an annual bonus of up
to 25% of Employee’s Base Compensation, which bonus shall be paid in the normal cycle of payment of executive bonuses (which bonus payment shall occur in the first quarter of the fiscal year following the fiscal year with respect to which the
bonus is earned) and upon achievement and satisfaction of goals and objectives (“Goals and Objectives”) established upon mutual agreement of the CEO, Employee and the Compensation Committee of the Company’s Board. Such goals shall be
established concurrently with the goals and objectives of the Company’s other senior executives. Notwithstanding anything to the contrary herein, Employee’s bonus for 2009 will be a guaranteed $50,000 and in order to receive any bonus
under this Section 3(b) Employee must be an employee of the Company at the time of the bonus payout. 
 (c)
Equity Compensation. 
 (i) On the Effective Date, the Employee will be granted options to purchase Four Hundred Thousand
(400,000) shares of the Company’s common stock (the “Options”) under the Company’s 2002 Equity Incentive Plan (the “Plan”) (a copy of which is attached as Exhibit B), with an exercise price at the fair
market value of the Company common stock on the date Effective Date. Subject to accelerated vesting or termination as set forth herein, the Standard Options shall vest in equal annual installments over three (3) years measured from the
Effective Date. 
 (ii) In addition, on the Effective Date, Employee will be issued One Hundred Thousand (100,000) shares of
restricted stock under the Plan (the “Restricted Shares”). The Restricted Shares shall vest as follows: 
 through the
first anniversary of the Effective Date (a) in a pro rata basis upon execution by the Company of any licensing agreements or similar alliance 

  
 2 

 
transactions which generate upfront payments to the Company of a minimum of $10 million and a maximum of $20 million in aggregate payments in this period; and (b) 100% upon any Change of
Control. By way of illustration and not limitation, in the event that the aggregate payments referenced above total $10 million, no Restricted Shares would vest; if such payments total $15 million, 50,000 Restricted Shares would vest; if such
payments total $18 million, 80,000 Restricted Shares would vest; and if such payments total $20 million or more, 100,000 Restricted Shares would vest 
 (iii) The exercise price of the Options and all other terms and conditions associated with the Options and Restricted Shares shall be determined in accordance with the Plan and grants (the forms of which
are annexed hereto as Exhibit C and Exhibit D, respectively). To the maximum extent possible, the Options shall be Incentive Stock Options. 
 (d) Additional Compensation. Within 10 business days of the Effective Date, the Company will pay the Employee a $100,000 sign-on bonus. Should the Employee separate from the Company prior to the
one year anniversary of the Effective Date for reasons of termination for Cause or voluntary termination by the Employee other than for Good Reason, this sign-on bonus is refundable to Company in full. 

 

	4.	Expenses. 

 The Company
will reimburse Employee for all expenses reasonably incurred by him in discharging his duties for the Company, conditioned upon Employee’s submission of written documentation in support of claimed reimbursement of such expenses, and consistent
with the Company’s expense reimbursement policies in effect from time to time. The Company will reimburse the Employee in 2010 up to One Hundred Twenty Thousand Dollars ($120,000) for reasonable expenses incurred in 2009 and 2010 to relocate
Employee, Employee’s spouse and parts of Employee’s and Employee’s Spouse’s household in a manner compatible with Employee’s duties hereunder to the Company’s headquarters location (“Facility Location”),
including the reasonable and customary costs of selling his Pennsylvania residence (but not vacant home carrying costs), shipment of personal effects to the Facility Location, and the customary closing costs associated with the purchase of a
residence in the Facility Location. In addition, Company shall reimburse Employee (or pay on Employee’s behalf) rent and related living expenses, not to exceed $2,500 per month in the aggregate and up to six (6) months in duration, for
temporary living arrangements and up to $5,000 for reasonable attorneys’ fees incurred in negotiation of this Agreement. 

  
 3 

	5.	Benefits. 

 Subject to
eligibility requirements, Employee shall be entitled to participate in such benefits plans and programs as adopted by the Company from time to time and shall be eligible for paid vacation of four (4) business weeks (20 business days) annually;
provided, however, if Employee does not use all available vacation in any given year, Employee may roll-over up to one business week (5 business days) to the following year, the parties intending that Employee shall have a maximum of five
(5) business weeks (25 business days) of paid vacation in any calendar year following 2009. Notwithstanding anything to the contrary herein, Employee shall receive 15 days paid vacation in 2009, available as of the Effective Date. Without
limiting the foregoing, subject to eligibility requirements, Employee shall be covered by any “directors and officers” insurance and “errors and omissions” insurance policies obtained by the Company. 

 

	6.	Confidentiality. 

 As a
condition to employment under this Agreement, Employee and the Company shall enter into the Non-Disclosure Agreement in the form attached hereto as Exhibit E. The provisions of this Section 6 shall survive termination of this
Agreement and term of employment. 
  

	7.	Non-competition and Non-solicitation. 

 (a) For a period of one (1) year in the case of the payment of severance equal to 12 months Base Compensation and for a period of two (2) years in the case of the payment of severance equal to
24 months Base Compensation, in both instances as provided in Section 12 below, Employee shall not directly or indirectly engage in or have any ownership interest in, or participate in the financing, operation, management or control of,
any person, firm, corporation or business listed on Exhibit F (as such shall be amended in the event that the Company enters into a material transaction with an entity not listed on Exhibit F and as shall be amended from time
to time by mutual consent of Employee and the Company); provided, however, that this provision shall not prohibit Employee from owning up to five percent (5%) of any class of outstanding bonds, preferred stock or shares of common stock
of any such entity or from employment with any institute of higher learning. 
 (b) For a period of two (2) years following
termination of employment with the Company for any reason, except with the express written consent of the Company, Employee agrees to refrain from directly or indirectly recruiting, hiring or assisting anyone else to hire, or otherwise counseling to
discontinue employment with the Company, any person then employed by the Company or its subsidiaries or affiliates; provided, however, nothing herein shall prevent Employee from providing, in accordance with Company policy, details regarding
the employment history of any such person or providing an employment reference with respect to such person. 
 (c) In the event
that the provisions of this Section 7 should ever be deemed to exceed the duration or geographic limitations or scope permitted by applicable law, then 

  
 4 

 
such provisions shall be reformed to the maximum time or geographic limitations or scope, as the case may be, permitted by applicable laws. 

(d) The provisions of this Section 7 shall survive termination of this Agreement and the term of employment. 

 

	8.	Covered Work. 

 (a) All
rights, title and interest to any Covered Work that Employee makes or conceives (whether alone or with others) while employed by the Company, belong to the Company. This Agreement operates as an actual assignment of all rights in Covered Work to the
Company. “Covered Work” means products and Inventions that relate to the actual or anticipated business of the Company or any of its subsidiaries or affiliates, or that result from or are suggested by a task assigned to Employee or work
performed by Employee on behalf of the Company or any of its subsidiaries or affiliates, or that were developed in whole or in part on the Company time or using the Company’s equipment, supplies or facilities. “Inventions” mean ideas,
improvements, designs, computer software, technologies, techniques, processes, products, chemicals, compounds, materials, concepts, drawings, authored works or discoveries, whether or not patentable or copyrightable, as well as other newly
discovered or newly applied information or concepts. Attached hereto as Exhibit G is a description of any product or Invention in which Employee had or has any right, title or interest, which is not included within the definition of
Covered Work or which is otherwise excluded from the restrictions set forth in this Section 8. 
 (b) Employee shall
promptly reveal all information relating to Covered Work and Confidential Information to an appropriate officer of the Company and shall cooperate with the Company, and execute such documents as may be necessary, in the event that the Company
desires to seek copyright, patent or trademark protection thereafter relating to same. 
 (c) In the event that the Company
requests that Employee assist in efforts to defend any legal claims to patents or other right, the Company agrees to reimburse Employee for any reasonable expenses Employee may incur in connection with such assistance. This obligation to reimburse
shall survive termination of this Agreement and the term of employment. 
 (d) The provisions of this Section 8
shall survive termination of this Agreement and the term of employment. 
  

	9.	Return of Inventions, Products and Documents. 

 Employee acknowledges and agrees that all Inventions, all products of the Company and all originals and copies of records, reports, documents, lists, drawings, memoranda, notes, proposals, contracts and
other documentation related to the business of the Company or containing any information described in this Section 9 shall be the sole and exclusive property of the Company and shall be returned to the Company immediately

  
 5 

 
upon termination of Employee’s employment with the Company or upon the written request of the Company. The provisions of this Section 9 shall survive termination of this
Agreement and the term of employment 
  

	10.	Injunction. 

 Employee
agrees that it would be difficult to measure damages to the Company from any breach by Employee of Sections 6, 7, 8 and/or 9 of this Agreement, and that monetary damages would be an inadequate remedy for any such breach.
Accordingly, Employee agrees that if Employee shall breach Sections 6, 7, 8 and/or 9 of this Agreement, the Company shall be entitled, in addition to all other remedies it may have at law or in equity, to an injunction or other
appropriate orders to restrain any demonstrated breach without showing or proving any actual damage sustained by the Company. The provisions of this Section 10 shall survive termination of this Agreement and the term of employment.

  

	11.	Obligations to Others. 

Except for items fully disclosed in writing to the Company (including with respect to the entities and agreements listed on
Exhibit H), Employee represents and warrants to the Company that (i) Employee’s employment by the Company does not violate any agreement with any prior employer or other person or entity, and (ii) Employee is not subject
to any existing confidentiality or non-competition agreement or obligation, or any agreement relating to the assignment of Inventions except as has been fully disclosed in writing to the Company. Notwithstanding anything to the contrary, if any
agreement listed on Exhibit H shall interfere or limit in any material manner the performance of Employee’s duties hereunder, prior to commencement of employment Employee shall disclose the material terms of such agreements to
Company. 
  

	12.	Termination and Termination Compensation 

 (a) Employee may voluntarily terminate his employment with the Company upon giving the Company sixty (60) days written notice. 

(b) The Company may terminate Employee’s employment without Cause (as defined below) upon giving Employee thirty (30) days
written notice of termination. 
 (c) Employee’s employment with the Company shall terminate upon the occurrence of any one
of the following: 
 (i) Employee’s death; 
 (ii) The effective date of a notice sent to Employee stating the Board’s determination made in good faith and after consultation with a qualified physician selected by the Board, that Employee is
incapable of performing his duties under this Agreement, with reasonable accommodation, because of a physical or mental incapacity that has prevented Employee from performing such full-time duties for a period of ninety (90) consecutive
calendar days and 

  
 6 

 
the determination that such incapacity is likely to continue for at least another ninety (90) days; provided, however, termination under this Section 12(c)(ii) shall not
affect Employee’s eligibility nor modify the terms and conditions under the Company’s long term disability policies, if any, existing at the time of such termination; or 

(iii) The effective date of a notice sent to Employee terminating Employee’s employment for Cause. 

(iv) “Cause” means the occurrence of one or more of the following events: 

(A) Employee’s willful and repeated failure or refusal to comply in any material respect with the reasonable lawful
policies, standards or regulations from time to time established by the Company, or to perform his duties in accordance with this Agreement after notice to Employee of such failure and after Employee has been given a reasonable period of time to
cure such failure to comply; or 
 (B) Employee is convicted of, or pleads guilty or nolo contendere to, a
felony or demonstrably engages in misconduct that is materially detrimental to the reputation, character or standing of the Company. 
 (v) Following any termination of the Employee’s employment hereunder (by the Employee or by the Company), the Employee will be entitled to receive (i) any earned but unpaid Base Compensation
through the date of termination, (ii) any unreimbursed business expenses, (iii) any benefits under the Company’s compensation plan that by their terms provide for cash payments of accrued but unused benefits and under applicable law
(collectively, the “Accrued Obligations”). 
 (vi) Upon Employee’s voluntary termination of employment, other than
voluntary termination with Good Reason (as defined below), or upon termination of employment by the Company for Cause, the Company shall pay to Employee the Accrued Obligations, but shall have no further obligation to Employee hereunder in respect
of any period following termination. 
 (vii) Upon the death of Employee, the Company shall pay to Employee’s estate or such
other party who shall be legally entitled thereto, the Accrued Obligations and an additional amount equal to compensation at the rate set forth in this Agreement or then current annual salary rate, whichever is greater, from the date of death to the
final day of the month following the month in which the death occurs. 
 (viii) (A) Upon termination of Employee’s
employment by the Company other than for Cause and other than in connection with or after a Change in Control, in addition to the Accrued Obligations, the Company shall pay to 

  
 7 

 
Employee twelve (12) months of Base Compensation, with such payment to be made in a lump sum payment within sixty (60) days of such termination of employment. In addition, all nonvested
Options, Restricted Stock Units and other long term compensation benefits then in effect shall immediately vest and be exercisable for a period of 180-days following the effective date of termination. 

(B) Upon termination by the Company other than for Cause in connection with or after a Change in Control or upon
Employee’s voluntary termination of employment for Good Reason in connection with or within twenty-four (24) months after a Change of Control, in addition to the Accrued Obligations, the Company shall pay to Employee twenty-four
(24) months of Base Compensation, with such payment to be made in a lump sum payment within sixty (60) days of such termination of employment. In addition, all nonvested Options, Restricted Stock Units and other long term compensation
benefits then in effect shall immediately vest and be exercisable for a period of 180-days following the effective date of termination. 
 (ix) Any amounts payable under this Section 12 shall be net of amounts required to be withheld under applicable law and amounts requested to be withheld by Employee. 

(x) As used herein, “Good Reason” shall mean, following a Change of Control (as such term is defined below), the termination by
Employee upon the occurrence of any of the below described events. The Employee must provide notice to the Company of the existence of such event within ninety (90) days of the first occurrence of such event, and the Company will have thirty
(30) days to remedy the condition, in which case no Good Reason shall exist. If the Company fails to remedy the condition within such thirty (30) day period, the Employee must terminate employment within two (2) years of the first
occurrence of such event. The events which constitute a Good Reason termination are: 
 (A) The assignment of a
different title or change that results in a material reduction in Employees duties or responsibilities; 
 (B) A
reduction by the Company in Employee’s Base Compensation, other than a salary reduction that is part of a general salary reduction affecting employees generally and provided the reduction is not greater, percentage-wise, than the reduction
affecting other employees generally or failure to provide an annual increase in Base Compensation commensurate with other Employees; provided, however, in determining whether to provide an annual increase in Base Compensation commensurate with an
annual increase provided to other Employees, the Company may take into account factors such as market levels of compensation, Employee’s overall performance, and other factors reasonably considered by the

  
 8 

 
Company’s compensation committee and/or Board of Directors, so long as such determination is not made in bad faith with the intent to discriminate against Employee; or 

(C) Relocation of Employee’s principal place of business of greater than seventy-five (75) miles from its then
location; provided, however, the current relocation of the Company’s headquarters to the Seattle, Washington metropolitan area shall not constitute Good Reason hereunder. 

(xi) As a condition of payment of the amounts set forth in this Section 12, if requested by Company with five
(5) business days of the Employee’s termination of employment, Employee agrees to enter into a Separation and Release Agreement substantially in the form attached hereto as Exhibit I. By way of clarification and not limitation,
if no separation payments are made under this Section 12, Employee shall not be required to execute a Separation and Release Agreement 
 (xii) As used herein, “Change of Control” means the occurrence of any one of the following events: (i) any person becomes the beneficial owner of twenty-five percent (25%) or more of
the total number of voting shares of the Company; (ii) any person (other than the persons named as proxies solicited on behalf of the Board of Directors of the Company) holds revocable or irrevocable proxies representing twenty-five percent
(25%) or more of the total number of voting shares of the Company; (iii) any person has commenced a tender or exchange offer, or entered into an agreement or received an option, to acquire beneficial ownership of twenty-five percent
(25%) or more of the total number of voting shares of the Company; and (iv) as the result of, or, in connection with, any cash tender or exchange offer, merger, or other business combination, sale of assets, or any combination of the
foregoing transactions, the persons who were directors of the Company before such transactions shall cease to constitute at least two-thirds (2/3) of the Board of Directors of the Company or any successor entity. 

 

	13.	Notice. 

 Unless otherwise
provided herein, any notice, request, certificate or instrument required or permitted under this Agreement shall be in writing and shall be deemed “given” upon personal delivery to the party to be notified or two business days after
deposit for next day delivery with Federal Express or similar courier service, addressed to the party to receive notice at the address set forth above, postage prepaid. Either party may change its address by notice to the other party given in the
manner set forth in this Section. 
  

	14.	Entire Agreement. 

 This
Agreement constitutes the entire agreement between the parties and contains all the agreements between them with respect to the subject matter hereof. It also 

  
 9 

 
supersedes any and all other agreements or contracts, either oral or written, between the parties with respect to the subject matter hereof; provided, however, in the event any of
Sections 6, 7, 8, 9, or 10 of this Agreement is found unenforceable in any way, then such section shall be amended to the extent necessary to conform to applicable law. 

 

	15.	Modification. 

 Except as
otherwise specifically provided, the terms and conditions of this Agreement may be amended at any time by mutual agreement of the parties, provided that before any amendment shall be valid or effective, it shall have been reduced to writing and
signed by an authorized representative of the Company and Employee. 
  

	16.	No Waiver. 

 The failure
of any party hereto to exercise any right, power or remedy provided under this Agreement or otherwise available in respect hereof at law or in equity, or to insist upon compliance by any other party hereto with its obligations, shall not be a waiver
by such party of its right to exercise any such or other right, power or remedy or to demand compliance. 
  

	17.	Severability. 

 In the
event that any section or provision of this Agreement shall be held to be illegal or unenforceable, such section or provision shall be severed from this Agreement and the entire Agreement shall not fail as a result, but shall otherwise remain in
full force and effect. 
  

	18.	Assignment 

 This
Agreement shall be binding upon and inure to the benefit of the Company and its successors and assigns, and shall be binding upon Employee, his administrators, executors, legatees, and heirs. In that this Agreement is a personal services contract,
it shall not be assigned by Employee. 
  

	19.	Dispute Resolution. 

Except as otherwise provided in Section 10, the Company and Employee agree that any dispute relating to the rights and
obligations under this Agreement between Employee and the Company or its officers, directors, employees, or agents in their individual or Company capacity of this Agreement, shall be submitted to a mediator mutually acceptable to both parties for
nonbinding, confidential mediation. If the matter cannot be resolved with the aid of the mediator within 30 days, the Company and Employee mutually agree to arbitration of the dispute. The arbitration shall be in accordance with the then-current
Employment Dispute Resolution Rules of the American Arbitration Association before an arbitrator who is licensed to practice law in the State of Washington. The arbitration shall take place in or near Seattle, Washington. Employee and the Company
will share bear the cost of the arbitration equally, but each party will bear their own costs and legal fees associated with the arbitration; provided, however, if any party prevails on a statutory claim,

  
 10 

 
which affords the prevailing party attorneys’ fees, or if there is a written agreement providing for attorneys’ fees, the arbitrator may award reasonable attorneys’ fees. The
Company and Employee agree that the procedures outlined in this provision are the exclusive method of dispute resolution. 
  

	20.	Attorneys Fees. 

 In the
event suit or action is instituted pursuant to Section 10 or Section 19 of this Agreement, the prevailing party in such proceeding, including any appeals thereon, shall be awarded reasonable attorneys fees and costs;
provided, however, except with respect to claims found to be friviolous or entirely without merit, the amount of such fees to be paid by the non-prevailing party shall not exceed $50,000. 

 

	21.	Applicable Law. 

 This
Agreement shall be construed and enforced under and in accordance with the laws of the State of Washington. 
  

	22.	Section 409A; Section 280G. 

 (a) It is the intention of the parties to this Agreement that no payment or entitlement pursuant to this Agreement will give rise to any adverse tax consequences to Employee or the Company with regard to
Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”). This Agreement shall be interpreted to that end and consistent with that objective. The Company and the Employee shall, to the extent
necessary to comply with Section 409A and permitted thereunder, agree to act reasonably and in good faith to mutually reform the provisions of this Agreement to avoid the application of the additional tax and interest under
Section 409A(a)(1)(B), provided that any such reformation shall not negatively impact the economics of the Company or the Employee hereunder. Notwithstanding any other provision herein, if Employee is a “specified employee,” as
defined in, and pursuant to, Treasury Regulation Section 1.409A-1(i) or any successor regulation, on the date of termination, no payment of any “deferred compensation”, as defined under Treasury Regulation Section 1.409A or any
successor regulation, shall be made to Employee during the period lasting until the earlier of six (6) months from the date of termination or upon Employee’s death. If any payment to Employee is delayed pursuant to the foregoing sentence,
such payment instead shall be made on the first business day following the expiration of the six (6) month period referred to in the prior sentence or, if in the case of Employee’s death, promptly thereafter. 

Except as otherwise specifically provided in this Agreement, if any reimbursement to which the Employee is entitled under this Agreement
would constitute deferred compensation subject to Section 409A of the Code, the following additional rules shall apply: (i) the reimbursable expense must have been incurred, except as otherwise expressly provided in this Agreement, during
the term of this Agreement; (ii) the amount of expenses eligible for reimbursement during any calendar year will not affect the amount of expenses eligible for reimbursement in any other calendar year; (iii) the reimbursement

  
 11 

 
shall be made not later than December 31 of the calendar year following the calendar year in which the expense was incurred; and (iv) the Employee’s entitlement to reimbursement
shall not be subject to liquidation or exchange for another benefit. 
 With regard to any installment payment, each installment
thereof shall be deemed a separate payment for purposes of Section 409A of the Code. 
 (b) Section 280G 

(i) Notwithstanding any provision of this Agreement to the contrary, except as provided below, if it is determined that the payments or
benefits to which Employee will be entitled under Section 12 of the Agreement or otherwise under any other agreement, policy, plan, program or arrangement (a “Payment”), would be subject to an excise tax (“Excise
Tax”) under Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”), but for the application of this sentence, then the Payments will be reduced to the minimum extent necessary (but in no event below zero) so
that no portion of any such Payment, as so reduced, constitutes an “excess parachute payment” within the meaning of Section 280G of the Code. 
 (ii) The limitation above will not apply if: 
 the difference between 

(1) the present value of all payments to which Employee is entitled under Section 12 of the Agreement determined without
regard to the limitation above, less 
 (2) the present value of all federal, state, and other income and excise taxes for which
Employee is liable as a result of such payments; exceeds 
 the difference between 

(1) the present value of all payments to which Employee is entitled under Section 12 of the Agreement calculated as if the
limitation above applies, less 
 (2) the present value of all federal, state, and other income and excise taxes for which
Employee is liable as a result of such reduced payments. 
 (iii) All determinations required to be made under this
Section 21, including whether an Excise Tax is payable by the Employee and the amount of such Excise Tax, shall be made by a nationally recognized accounting firm designated by the Company (the “Accounting Firm”). The Company
shall direct the Accounting Firm to submit its determination and detailed supporting 

  
 12 

 
calculations to the Company and the Employee within fifteen (15) calendar days after the date of the Employee’s termination of employment, and other such time or times as may be
requested by the Company or the Employee. If the Accounting Firm determines that no Excise Tax is payable by the Employee, it shall, at the same time as it makes such determination, furnish the Employee with an opinion that the Employee has
substantial authority not to report any Excise Tax on the Employee’s federal, state, local income or other tax return. The Company and the Employee shall each provide the Accounting Firm access to and copies of any books, records and documents
in the possession of the Company or the Employee, as the case may be, reasonably requested by the Accounting Firm in connection with the preparation and issuance of the determination contemplated by this Section 22. Any reasonable
determination made by the Accounting Firm under this Section 22 shall be binding upon the Company and the Employee. All fees and expenses of the Accounting Firm shall be borne solely by the Company. 

(iv) The reduction of the amounts payable hereunder shall be made in a manner consistent with the requirements of Section 409A of the
Code. The reduction of the amounts payable hereunder, if applicable, shall be made by first reducing, but not below zero, any amounts due to the Employee pursuant to the Company’s equity plans shall be reduced on a pro-rata basis. In the event
that following the reduction of the amounts set forth in the preceding sentence, additional amounts payable to the participant must be reduced, the cash payments under Section 12 shall be reduced on a pro-rata basis, but not below zero.

  

	23.	Counterparts. 

 This
Agreement may be signed in two counterparts, each of which shall be deemed an original and both of which shall together constitute one agreement. 
 [SIGNATURE PAGE FOLLOWS] 

  
 13 

 IN WITNESS WHEREOF, AVI BioPharma, Inc. has caused this Agreement to be signed by its duly
authorized representative, and Employee has hereunder set his name as of the date of this Agreement. 
  

			
	COMPANY: AVI BioPharma, Inc.
		
	By:	 	/s/ Leslie Hudson
		 	Leslie Hudson, PhD, Chief Executive Officer
	
	EMPLOYEE:
	
	/s/ Paul Medeiros
	Paul Medeiros

  
 14 

 EXHIBIT A 

LIST OF OFFICES HELD 

None 

  
 15 

 EXHIBIT B 

COMPANY’S 2002 EQUITY INCENTIVE PLAN 
  

 

  
 16 

 EXHIBIT C 

STOCK OPTION AGREEMENT 

  
 17 

 EXHIBIT D 

RESTRICTED STOCK AGREEMENT 

  
 18 

 EXHIBIT E 

CONFIDENTIAL 
 NON-DISCLOSURE AGREEMENT 
 This Non-Disclosure Agreement (this
“Agreement”) is entered into as of             , 2009 (the “Effective Date”), by and between AVI BioPharma, Inc., an Oregon corporation
(“AVI”) and Paul Medeiros (“Employee”) (each, a “Party” and, collectively, the “Parties”). 
 RECITALS 
 A. Employee will be engaged as an employee to provide services
to AVI (the “Services”) as an at will employee under Oregon law in accordance with that certain Employment Agreement between AVI and Employee dated as of the date hereof. 

B. Employee will have access to certain material, non-public information about AVI. 

C. As a condition precedent to providing such information to the Employee in connection with the Services and Employee’s employment,
the Parties have agreed to enter into this Agreement. 
 D. This Agreement replaces and supersedes that certain Non-Disclosure
Agreement between AVI and Employee dated             , 2009. 

NOW, THEREFORE, in consideration of the mutual covenants expressed herein and other valuable consideration, the receipt and sufficiency
of which are acknowledged, the Parties, intending to be legally bound, agree as follows. 
 AGREEMENT 

1. Definitions. For the purposes of this Agreement: 
  

	 	1.1	“Affiliate” of a Party means any entity that a Party directly or indirectly controls, or is controlled by, including but not limited to employees,
agents, and entities. 

  

	 	1.2	“Confidential Information” means any business, marketing, technical, or other information in tangible or intangible form disclosed by AVI to Employee
that, at the time of disclosure, is designated as confidential (or like designation), is disclosed in circumstances of confidence, or would be understood by the Parties (or their Affiliates and Representatives), exercising reasonable business
judgment, to be confidential, specifically including AVI business plans, product concepts, technical know-how, methods of and other information relating to operations, development strategies, distribution arrangements, financial data, marketing
plans, and business practices, policies, or objectives. 

  
 19 

	 	1.3	“Representative” means, with respect to either Party, such Party’s members, managers, partners, Affiliates, attorneys, advisors, potential lenders,
potential co-investors, directors, officers, employees, agents or representatives. 

 2. Disclosure, Use Restrictions and
Proprietary Rights. 
  

	 	2.1	Disclosure and Use. 

  

	 	(a)	Except as expressly provided in this Agreement, Employee shall retain all Confidential Information in confidence and shall not directly or indirectly, disclose reveal,
divulge, publish or otherwise make known any of the Confidential Information for any reason or purpose whatsoever without AVI’s prior written consent, which may be withheld at AVI’s sole discretion, and solely on a need to know basis used
only in accordance with this Agreement. Employee shall take all steps necessary to safeguard and protect the Confidential Information from unauthorized access, use or disclosure by or to others, including but not limited to, maintaining appropriate
security measures. The obligations of confidence set forth in this Agreement shall extend to any of Employee’s Representatives that may receive Confidential Information and Employee shall be responsible for any breach of this Agreement by its
Representatives. 

  

	 	(b)	In accordance with Section 2.4 below, Employee shall notify AVI immediately upon discovery of any unauthorized use or disclosure of Confidential Information
or any other breach of this Agreement by Employee, its Representatives, and will cooperate with AVI to assist AVI to regain possession of the Confidential Information and prevent its further unauthorized use or disclosure. 

 

	 	2.2	Exemptions. Employee shall not be bound by the obligations restricting disclosure and use set forth in this Agreement with respect to Confidential Information,
or any part thereof, which: (i) was known by Employee prior to disclosure; (ii) was lawfully in the public domain prior to its disclosure, or becomes publicly available other than through a breach of this Agreement; (iii) was
disclosed to Employee by a third party, provided such third party is not in breach of any confidentiality obligation in respect of such information; (iv) is independently developed by Employee, where the burden is on Employee to prove
independent development; or (v) is disclosed when such disclosure is compelled pursuant to legal, judicial or administrative proceedings, or otherwise required by law, subject to Employee giving reasonable prior notice to AVI Party to allow AVI
to seek protective court orders. The foregoing exemptions shall extend to any Representatives that receive or have received Confidential Information. 

  

	 	2.3	 Proprietary Rights. Employee (including its Representatives) shall not acquire any rights, express or implied, in the Confidential Information
of AVI (including its Affiliates), except for the limited use specified in this Agreement. The Confidential 

  
 20 

	 	 
Information, including all right, title and interest therein, remains the sole and exclusive property of AVI (and its Affiliates). 

 

	 	2.4	Compulsory Disclosure. If Employee is legally compelled to disclose any of the Confidential Information, Employee shall promptly provide written notice to AVI to
enable AVI (at its sole cost and expense) to seek a protective order or other appropriate remedy to avoid public or third-party disclosure of its Confidential Information. If such protective order or other remedy is not obtained, Employee shall
furnish only so much of the Confidential Information that it is legally compelled to disclose, and shall exercise its commercially reasonable efforts to obtain reliable assurance that confidential treatment will be accorded the Confidential
Information. Employee shall cooperate with and assist AVI, at AVI’s expense, in seeking any protective order or other relief requested pursuant to this Section 2.4. 

3. Ownership of Work Product. 
  

	 	3.1	“Work Product” means any information, created by Employee, AVI, and/or jointly by Employee and AVI during Employee’s employment with AVI in connection
with AVI’s research, development and commercialization of drugs and related products, including but not limited to, data, reports, analysis, summaries, formulae, ideas, research, developments, inventions (patentable or not), processes, designs,
drawings, works, clinical data and analysis, biological materials, chemical formulas, trade secrets, concepts, know-how, improvements, techniques, products, and any and all results of the research and development process. 

 

	 	3.2	Employee agrees that any and all Work Product shall be considered work made for hire and belong exclusively to AVI. In the event any such Work Product are not eligible
for treatment as work for hire under applicable law, Employee hereby assigns Employee’s entire right, title, and interest in and to the Work Product and/or any data, reports, analysis, summaries, formulae, ideas, research, developments,
inventions (patentable or not), processes, designs, drawings, works, clinical data and analysis, biological materials, chemical formulas, trade secrets, concepts, know-how, improvements, techniques, products, and any and all results of the research
and development process, made or conceived solely or jointly by Employee in connection with Employee’s employment by AVI (“Company Inventions”). Employee agrees that he shall promptly disclose any such Company Inventions to AVI, and,
upon request, he shall promptly execute a specific assignment of title to AVI, and do anything else reasonably necessary (whether during or after the term of Employee’s employment with AVI) to enable AVI to secure a patent or copyright
protection therefor in the United States and foreign countries. 

 4. Remedies. Employee acknowledges and agrees that the
provisions of this Agreement are of a special and unique nature, the loss of which cannot be accurately compensated for in damages by an action at law, and that the breach or threatened breach of this Agreement by the Employee or any of its
Representatives would cause AVI and its Affiliates irreparable harm and that money damages would not be an adequate remedy. Employee agrees on behalf of itself and its Representatives that 

  
 21 

 
AVI (and its Affiliates) shall be entitled to equitable relief, including, without limitation, an injunction or injunctions (without the requirement of posting a bond, other security or any
similar requirement or proving any actual damages), to prevent breaches or threatened breaches of this Agreement by Employee or any of its Representatives and to specifically enforce the terms and provisions of this Agreement, this being in addition
to any other remedy to which AVI (or its Affiliates) may be entitled at law or in equity. 
 5. Indemnification. Employee shall indemnify
and defend AVI and its Representatives and each of their respective directors, officers, employees, managers, members, partners, shareholders, agents and affiliates (collectively, the “Indemnified Persons”) against and hold each
Indemnified Person harmless from any and all liabilities, obligations, losses, damages, costs, expenses, claims, penalties, lawsuits, proceedings, actions, judgments, disbursements of any kind or nature whatsoever, interest, fines, settlements and
reasonable attorneys’ fees and expenses that the Indemnified Persons may incur, suffer, sustain or become subject to arising out of, relating to, or due to the breach of this Agreement by Employee or any of its Representatives. The provisions
of this Section 4 shall survive indefinitely any termination of this Agreement, the completion or the termination of Employee’s employment. 
 6. Securities Laws. Employee hereby acknowledges that AVI is a publicly traded company. Employee hereby acknowledges that Employee is aware that federal and state securities laws prohibit any
person who has received material, non-public information (information about AVI or its business that is not generally available to the public) concerning AVI, including, without limitation, the matters that are the subject of this Agreement, from
purchasing or selling securities of AVI while in possession of such non-public information, and from communicating that information to any other person who may purchase or sell securities of AVI or otherwise violate such laws. Employee specifically
acknowledges these obligations and agrees to be bound by them, including, without limitation, AVI’s insider trading policies in existence as of the Effective Date and as may be adopted or changed in the future. 

7. Term of Confidentiality Obligation. 
  

	 	7.1	Term. The confidentiality obligations set forth in this Agreement shall continue with regard to an item of information as long as that information continues to
meet the definition of “Confidential Information” and is not exempt under Section 2.2. 

  

	 	7.2	Return of Confidential Information. At any time upon written request by AVI, Employee shall return or destroy all documents or other materials embodying
Confidential Information, shall retain no copies thereof, and shall certify in writing that such destruction or return has been accomplished. The confidentiality obligations set forth in this Agreement shall survive any termination of the Agreement.

 8. General. 

  
 22 

	 	8.1	Waiver. The failure of AVI to claim a breach of any term of this Agreement shall not constitute a waiver of such breach or the right of AVI to enforce any
subsequent breach of such term. 

  

	 	8.2	Assignment. This Agreement shall be binding on and inure to the benefit of each Party and their respective successors and assigns. 

 

	 	8.3	Severability. In the event that any provision of this Agreement is found to be invalid, void or unenforceable, the Parties agree that unless such provision
materially affects the intent and purpose of this Agreement, such invalidity, void ability or unenforceability shall not affect the validity of this Agreement nor the remaining provisions herein. 

 

	 	8.4	Governing Law. This Agreement shall be governed by the laws of the State of Oregon, without regard to its conflict of law principles. The Parties agree that the
exclusive jurisdiction for any legal action shall be Benton County, Oregon. 

  

	 	8.5	Entire Agreement. This Agreement constitutes the entire agreement between the parties on the subject matter hereof and supersedes all prior agreements,
communications and understandings of any nature whatsoever, oral or written. This Agreement may not be modified or waived orally and may be modified only in a writing signed by a duly authorized representative of both parties. Nothing herein shall
constitute an offer or guarantee of future employment for Employee by AVI. 

 IN WITNESS WHEREOF, the Parties have
caused this Agreement to be executed by their duly authorized representatives and to be effective on the Effective Date. 
  

									
	AVI	 		 	EMPLOYEE
					
	By:	 	/s/ Leslie Hudson	 		 	By:	 	/s/ Paul Medeiros
	Name:	 	Dr. L. Hudson	 		 	Name:	 	Paul Medeiros
	Title:	 	President and CEO	 		 	Title:	 	 
	Date:	 	May 18, 2009	 		 	Date:	 	May 18, 2009

  
 23 

 EXHIBIT F 

LIST OF ENTITIES NON-COMPETE 
  

 
 ISIS Pharmaceuticals, Inc.

 Santaris Pharma A/S 
 Prosensa, B.V.

 ALNYLAM, Inc. 
 Santheria AG

 (List to be updated prior to execution) 

  
 24 

 EXHIBIT G 

NON-COVERED WORK 

  
 25 

 EXHIBIT H 

EMPLOYEE’S ONGOING CONFIDENTIALITY OBLIGATIONS 

 
  
 Schering-Plough Corporation, Kenilworth, NJ 
 Merck & Company, Whitehouse Station, NJ

 Locust Walk Partners, Penn Valley, PA 

Cranwell Group, West Windsor, NJ 

  
 26 

 EXHIBIT I 

SEPARATION AND RELEASE AGREEMENT 
 THIS SEPARATION AND RELEASE AGREEMENT (“Agreement”) is between Paul Medeiros (“Employee”) and AVI BioPharma, Inc. (“Employer”), and is effective eight
(8) days after Employee signs this Agreement (“Effective Date”). 
 The parties agree as follows:

 1. Resignation. Employee resigned his position as Employer’s [Title] effective [effective date of termination]
(the “Resignation Date”). Employee has been paid his salary and other compensation through the Resignation Date, less all lawful or required deductions. 
 2. Consideration. In consideration of Employee’s agreements hereunder, Employer shall pay to Employee the amounts set forth and described in
Section                      of that certain Employment Agreement dated effective the
                     day of     , 2009. 
 3. Return of Employer Property. Employee represents that he has returned all Employer property in his possession or under his control, including but not limited to keys, credit cards, files, laptop
computer and any and all Employer documents. 
 4. Confidentiality. The parties will use reasonable efforts to keep the
terms of this Agreement confidential. Employee may disclose the terms of this Agreement to his immediate family. Employer may disclose the terms of this Agreement to its officers and managers. Either party may disclose the terms of this Agreement to
their respective attorneys, accountants, financial advisers, auditors, or similar advisors, or in response to government requests. Third persons informed of the terms of this Agreement shall in turn be advised of this confidentiality provision and
requested to maintain such confidentiality. 
 5. Release. 

5.1 In exchange for the consideration paid to Employee as set forth in this Agreement, Employee forever releases and discharges Employer,
any of Employer-sponsored employee benefit plans in which Employee participates, or was participating in, (collectively the “Plans”) and all of their respective officers, members, managers, partners, directors, trustees, agents,
employees, and all of their successors and assigns (collectively “Releases”) from any and all claims, actions, causes of action, rights, or damages, including costs and attorneys’ fees (collectively “Claims”)
which Employee may have arising out of his employment (including Claims that may arise out of Employee’s employment agreement), on behalf of himself, known, unknown, or later discovered which arose prior to the date Employee signs this
Agreement. This release includes but is not limited to, any Claims under any local, state, or federal laws prohibiting discrimination in employment, including without limitation the federal civil rights acts, Oregon Revised Statutes Chapter 659A,
the Americans with Disabilities Act, the Age Discrimination in Employment Act, or Claims under the Employee Retirement Income Security Act, or Claims alleging any legal restriction on Employer’s right to terminate its employees, any Claims
Employee has relating to his rights to or 

  
 27 

 
against any of the Plans, or personal injury Claims, including without limitation wrongful discharge, breach of contract, defamation, tortious interference with business expectancy, constructive
discharge, or infliction of emotional distress. Employee represents that he has not filed any Claim against Employer or its Releases, he has no knowledge of any facts that would support any Claim by Employee against Employer or by a third party
against Employer, and that he will not file a Claim at any time in the future concerning Claims released in this Agreement; provided, however, that this will not limit Employee from filing a Claim to enforce the terms of this Agreement.
Notwithstanding the foregoing, nothing herein shall constitute release of any of Employee’s rights relating to vested options, vested benefits or vested entitlements under the Company’s employee benefits plans, including equity incentive
and retirement plans. 
 5.2 In consideration of the promises of Employee as set forth herein, Employer does hereby, and for its
successors and assigns, release, acquit and forever discharge Employee from any and all actions, causes of action, obligations, costs, expenses, damages, losses, claims, liabilities, suits, debts, and demands (including attorneys’ fees and
costs actually incurred), of whatever character in law or in equity known or unknown, suspected or unsuspected, from the beginning of time to the date of execution hereof. 
 6. Non-disparagement. Employee and Employer each agree not to make disparaging statements about each other, except in the case of Employer statements that are required under applicable federal or
state securities laws or applicable rules and regulations of any exchange on which Employer’s stock is traded. 
 7.
Consideration and Revocation Periods. Employee understands and acknowledges the significance and consequences of this Agreement, that it is voluntary, that it has not been given as a result of any coercion, and expressly confirms that it is
to be given full force and effect according to all of its terms, including those relating to unknown Claims. Employee was hereby advised of his right to seek the advice of an attorney prior to signing this Agreement. Employee acknowledges that he
has signed this Agreement only after full reflection and analysis. Although he is free to sign this Agreement before then, Employee acknowledges he was given at least 21 days after receipt of this document in which to consider it (the
“Consideration Period”). If Employee executes this Agreement prior to the end of the Consideration Period, Employee hereby waives any rights associated therewith. Employee may revoke this Agreement seven (7) days after signing
it and forfeit all benefits described in Section 13(c) of the Employment Agreement. Employee and Employer agree that any changes made to this Agreement during the Consideration Period as a result of negotiations between the parties do not
restart the running of the Consideration Period. 
 8. No Liability. This Agreement shall not be construed as an
admission by either party that it acted wrongfully with respect to the other. 
 9. Severability. If any of the
provisions of this Agreement are held to be invalid or unenforceable, the remaining provisions will nevertheless continue to be valid and enforceable. 
 10. Entire Agreement. This Agreement represents and contains the entire understanding between the parties in connection with its subject matter. All other prior written or oral agreements or
understandings are merged into and superseded by this Agreement. Employee acknowledges that 

  
 28 

 
in signing this Agreement, he has not relied upon any representation or statement not set forth in this Agreement made by Employer or any of its representatives. 

11. Attorney Fees. If any suit or action is filed by either party to enforce this Agreement or otherwise with respect to the
subject matter hereof, the prevailing party shall be entitled to recover reasonable attorney fees incurred in preparation or in prosecution or defense of such suit or action as fixed by the trial court, and if any appeal is taken from the decision
of the trial court, reasonable attorney fees as fixed by the appellate court. 
 12. Choice of Law. This Agreement is
made and shall be construed and performed under the laws of the State of Oregon. 
 PLEASE READ CAREFULLY. THIS AGREEMENT
INCLUDES A RELEASE OF CERTAIN KNOWN OR UNKNOWN CLAIMS. 
  

									
	DATED this day of      day of
                    , 20XX.	 		 	DATED this day of      day of
                    , 20XX.
			
	AVI BioPharma, Inc.	 		 	
					
	By:	 	 	 		 		 	 
	Name:	 		 		 		 	Paul Medeiros
	Title:	 		 		 		 	

  
 29 

 AVI BIOPHARMA, INC. 
 STOCK OPTION AGREEMENT 
 Incentive Stock Option 

This STOCK OPTION AGREEMENT is entered into the 19th day of May, 2009 (the “Grant Date”) by and between AVI BIOPHARMA, INC., an Oregon corporation (the
“Company”), and Paul Medeiros (the “Optionee”), pursuant to the Company’s 2002 Equity Incentive Plan (the “Plan”). The Company and the Optionee agree as follows: 

1. Option Grant. The Company hereby grants to the Optionee on the terms and conditions of this Agreement the right and the option
(the “Option”) to purchase all or any part of 400,000 shares of the Company’s Common Stock at a purchase price of $1.10 per share. To the maximum extent possible, the Option is intended to be and shall be treated as an
Incentive Stock Option, as defined in Section 422A of the Internal Revenue Code of 1986, as amended (the “Code”). To the extent the Option may not be treated as an Incentive Stock Option under the Code, the Option shall be
treated as a non-qualified option under the Code. 
 2. Terms and Conditions. The terms and conditions of the Option are
as set forth in the Plan, a copy of which is attached hereto as Exhibit A and as set forth in that certain Employment Agreement dated May 15, 2009, by and between the Company and Optionee, a copy of which is attached hereto as
Exhibit B (the “Employment Agreement”). In the event of a conflict between the Plan and the Employment Agreement, the terms and conditions of the Employment Agreement shall control. 

 

									
	AVI BIOPHARMA, INC.	 		 	OPTIONEE
					
	By:	 	/s/ Leslie Hudson	 		 		 	/s/ Paul Medeiros
	Name:	 	Leslie Hudson, Ph.D.	 		 		 	
	Title:	 	Chief Executive Officer	 		 		 	Paul Medeiros.
	 4575 SW Research Way

Suite 200
 Corvallis, OR 97333
	 		 		 	 Easton, PA 18042

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}]]